- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03657654
Voice Outcomes Following Thyroidectomy
Voice Outcomes Following Thyroidectomy Compared to Surgeries That Do Not Involve Risk to the Laryngeal Nerves
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Voice difficulty is a common complaint following thyroidectomy, and while the procedure risks injury to laryngeal nerves involved in voice production, voice difficulty is common even in the absence of evident injury to these nerves. The cause of voice change in these situations is not well defined, and multiple mechanisms have been suggested. Some potential mechanisms include trauma to the laryngeal skeleton from intraoperative manipulation of the strap muscles, cricothyroid muscle, thyroid, cartilage, or trachea. However, it is also possible that irritation due to intubation and edema to the neck and oral or pharyngeal soft tissues that develops after the surgery as a result of intubation plays a role in postoperative voice change. These mechanisms can occur in any operation requiring general endotracheal anesthesia even when the laryngeal nerves are not specifically at risk of injury.
The purpose of this study is to evaluate voice outcomes after thyroidectomy (both objective and subjective patient and clinician reported) and compare those to voice outcomes after other surgeries that do not put the recurrent or superior laryngeal nerves at risk or traumatize the laryngeal skeleton, but do require general endotracheal anesthesia. The primary assessment tool will be the Voice Handicap Index-10 (VHI-10), which is a questionnaire that asks about the patient's interpretation of his/her voice quality and the impact it is having on daily activities. Data analysis will be done to see if participants have a significant change in their pre-operation VHI-10 score at approximately 1 week and 3 months post-operation. Additional assessments tools will include nasolaryngoscopy and nasolaryngeal stroboscopy to assess global vocal fold function, Consensus Auditory Perceptual Evaluation of Voice (CAPE-V) and computerized speech lab (CSL) acoustics to assess voice quality, and vocal aerodynamic analysis to determine air flow through the larynx.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Bette F Ghamandi
- Phone Number: 434-243-1558
- Email: bjf8j@hscmail.mcc.virginia.edu
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- University of Virginia
-
Contact:
- Bette F Ghamandi, MHA, CCRP
- Phone Number: 434-243-1558
- Email: bjf8j@hscmail.mcc.virginia.edu
-
Sub-Investigator:
- James Daneiro, MD
-
Sub-Investigator:
- Bethany Horton, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Age ≥ 18 years
- Subject must be clinically referred for a thyroidectomy for known or potential cancer, or subject must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx for the control group
- As the VHI-10 is not available and validated in all languages, participants must be able to comprehend a validated version of the VHI-10 in their language
Exclusion Criteria:
- Plan to include neck dissection in upcoming surgery (control group/non-thyroidectomy patients only)
- Known to be pregnant
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Thyroidectomy
Patients that are clinically referred for a thyroidectomy for known or potential cancer.
|
No intervention: observational only
|
Other surgeries
Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
|
No intervention: observational only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Voice Handicap Index-10 (VHI-10) score before and after surgery
Time Frame: Baseline, 1 week following surgery, 3 months following surgery
|
This is a VHI-10 is a questionnaire that asks about the patient's interpretation of his/her voice quality and the impact it is having on daily activities.
|
Baseline, 1 week following surgery, 3 months following surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Video flexible nasolaryngoscopy
Time Frame: Within 24 hours following surgery
|
This procedure is endoscopic and allows for visualization and audio/video recording of the vocal folds at rest and during speech
|
Within 24 hours following surgery
|
Video nasolaryngeal stroboscopy
Time Frame: Baseline, 1 week following surgery, 3 months following surgery
|
This imaging is another form of nasolaryngoscopy but has the addition of a strobe light.
The strobe light provides an optical illusion in which the vocal cords appear to be moving in slow motion on the video, even though its movement is unaltered.
|
Baseline, 1 week following surgery, 3 months following surgery
|
Vocal Aerodynamics Analysis
Time Frame: Baseline, 1 week following surgery, 3 months following surgery
|
This assessment is performed by fitting the participant with a mask that is attached to a tube that goes just inside the participant's lips.
This positioning allows for the participant to close his/her lips around the tube without occluding it.
The participant is asked to produce repeated syllables like pi-pi-pi-pi-pi, which allows for airflow and air pressure to be measured and reflects vocal fold function.
|
Baseline, 1 week following surgery, 3 months following surgery
|
CAPE-V
Time Frame: Baseline, 1 week following surgery, 3 months following surgery
|
The CAPE-V is a tool used for clinical auditory-perceptual assessment of voice.
It is intended to describe the severity of various auditory attributes of a voice problem, and it is determined by the clinician's auditory assessment of the patient's voice.
|
Baseline, 1 week following surgery, 3 months following surgery
|
CSL acoustics
Time Frame: Baseline, 1 week following surgery, 3 months following surgery
|
This assessment involves having the participant speak into a microphone.
The patient says a few scripted sentences, as well as repeated sounds, which is then analyzed by the computer software.
The assessment allows for determination of vocal loudness, pitch, and voice quality.
Voice quality is determined based on measures including vocal shimmer, vocal jitter, and background noise in the voice.
Shimmer measures variation in voice amplitude and jitter measures variation in frequency.
|
Baseline, 1 week following surgery, 3 months following surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David C Shonka, MD, University of Virginia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20892
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Cancer
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Children's Hospital of PhiladelphiaBayerRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
Massachusetts General HospitalEli Lilly and CompanyRecruitingThyroid Carcinoma | Thyroid Cancer | Papillary Thyroid Cancer | Metastatic Thyroid Cancer | Follicular Thyroid Cancer | Unresectable Thyroid Gland CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
Clinical Trials on No intervention: observational only
-
University Hospital, Basel, SwitzerlandCompletedPostoperative Complications | Intraoperative Complications | Patient Safety | Risk ManagementNew Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
-
The First Affiliated Hospital of Zhengzhou UniversityBeijing Tiantan Hospital; National Health and Family Planning Commission, P...UnknownTransient Ischemic Attack | Minor StrokeChina
-
Xuanwu Hospital, BeijingRecruitingCoexistence of Cerebral and Coronary Atherosclerosis | Acute Ischemic Cerebrovascular DiseaseChina
-
University Medicine GreifswaldRecruitingMetabolic Syndrome | Chronic Heart FailureGermany
-
Xiang XieThe Third Affiliated Hospital of Jinzhou Medical University; Affiliated Traditional...Completed
-
Abant Izzet Baysal UniversityCompletedParkinson's Disease and ParkinsonismTurkey
-
Johannes Gutenberg University MainzRecruitingCoronary Artery Disease | Microvascular DysfunctionGermany
-
Illinois Institute of TechnologyTerminatedOsteoarthritis | Rheumatoid Arthritis | Chronic Pain | Chronic Low-back Pain | Osteoarthritis, Knee | Fibromyalgia | Osteoarthritis, Hip | Chronic Shoulder Pain | Ankylosing SpondylitisUnited States
-
Portsmouth Hospitals NHS TrustManchester Metropolitan UniversityCompletedRetrospective Observational Analysis of a Cohort With Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection FractionUnited Kingdom
-
Yefeng CaiUnknownStroke | Transient Ischemic Attack | Cerebral Infarction | Subarachnoid Hemorrhage | Cerebral HemorrhageChina